BR112017022958A2 - métodos para tratamento de câncer com inibidor da via da stat3 e inibidor de quinase - Google Patents

métodos para tratamento de câncer com inibidor da via da stat3 e inibidor de quinase

Info

Publication number
BR112017022958A2
BR112017022958A2 BR112017022958A BR112017022958A BR112017022958A2 BR 112017022958 A2 BR112017022958 A2 BR 112017022958A2 BR 112017022958 A BR112017022958 A BR 112017022958A BR 112017022958 A BR112017022958 A BR 112017022958A BR 112017022958 A2 BR112017022958 A2 BR 112017022958A2
Authority
BR
Brazil
Prior art keywords
methods
inhibitor
treating cancer
stat3 pathway
kinase inhibitor
Prior art date
Application number
BR112017022958A
Other languages
English (en)
Inventor
J Li Chiang
Rogoff Harry
Huang Janet
Li Youzhi
Gao Yuan
Original Assignee
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc
Publication of BR112017022958A2 publication Critical patent/BR112017022958A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)

Abstract

métodos compreendendo a administração e kits compreendendo pelo menos um composto da fórmula a: (a) pró-drogas, derivados, sais farmaceuticamente aceitáveis de qualquer um dos anteriores, e solvatos de qualquer um dos anteriores, e pelo menos um composto da fórmula b: (b) pró-drogas, derivados, sais farmaceuticamente aceitáveis de qualquer dos anteriores, e solvatos de qualquer um dos anteriores.
BR112017022958A 2015-04-27 2016-04-26 métodos para tratamento de câncer com inibidor da via da stat3 e inibidor de quinase BR112017022958A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562153385P 2015-04-27 2015-04-27
PCT/US2016/029328 WO2016176190A1 (en) 2015-04-27 2016-04-26 Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor

Publications (1)

Publication Number Publication Date
BR112017022958A2 true BR112017022958A2 (pt) 2018-07-17

Family

ID=56081544

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017022958A BR112017022958A2 (pt) 2015-04-27 2016-04-26 métodos para tratamento de câncer com inibidor da via da stat3 e inibidor de quinase

Country Status (16)

Country Link
US (1) US20180250261A1 (pt)
EP (1) EP3288552A1 (pt)
JP (2) JP2018514557A (pt)
KR (1) KR20170141716A (pt)
CN (1) CN107683137A (pt)
AU (1) AU2016255034A1 (pt)
BR (1) BR112017022958A2 (pt)
CA (1) CA2983468A1 (pt)
EA (1) EA201792320A1 (pt)
HK (1) HK1252172A1 (pt)
IL (1) IL255023A0 (pt)
MX (1) MX2017013816A (pt)
PH (1) PH12017501882A1 (pt)
SG (1) SG11201708506QA (pt)
TW (1) TW201713329A (pt)
WO (1) WO2016176190A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101854802B (zh) 2007-09-10 2014-12-03 北京强新生物科技有限公司 用于癌症治疗的组合物和方法
CA2908380A1 (en) 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer
WO2018005444A2 (en) * 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer
WO2022178957A1 (zh) * 2021-02-25 2022-09-01 毕庶壮 Napabucasin的制药用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2591028T3 (es) * 2007-09-06 2016-11-24 Boston Biomedical, Inc. Composiciones de inhibidores de quinasa y su uso para el tratamiento del cáncer y otras enfermedades relacionadas con quinasas
CN101854802B (zh) 2007-09-10 2014-12-03 北京强新生物科技有限公司 用于癌症治疗的组合物和方法
CA2908380A1 (en) * 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer

Also Published As

Publication number Publication date
JP2021121629A (ja) 2021-08-26
MX2017013816A (es) 2018-11-12
CA2983468A1 (en) 2016-11-03
HK1252172A1 (zh) 2019-05-17
EP3288552A1 (en) 2018-03-07
SG11201708506QA (en) 2017-11-29
PH12017501882A1 (en) 2018-03-05
KR20170141716A (ko) 2017-12-26
JP2018514557A (ja) 2018-06-07
US20180250261A1 (en) 2018-09-06
AU2016255034A1 (en) 2017-11-02
WO2016176190A1 (en) 2016-11-03
EA201792320A1 (ru) 2018-02-28
IL255023A0 (en) 2017-12-31
CN107683137A (zh) 2018-02-09
TW201713329A (zh) 2017-04-16

Similar Documents

Publication Publication Date Title
BR112017022958A2 (pt) métodos para tratamento de câncer com inibidor da via da stat3 e inibidor de quinase
CY1122247T1 (el) Αγωγη καρκινων με τη χρηση τροποποιητων ισομορφης κινασης ρι3
CO2018008761A2 (es) Derivados de maitansinoide, conjugados de los mismos métodos de uso
EA201792116A1 (ru) Ингибитор янус-киназы
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
ECSP18040250A (es) Composiciones y métodos para inhibir la actividad arginasa
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
BR112016024057A2 (pt) inibidores de quinases heterocíclicos
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CL2015002932A1 (es) Inhibidores de proteína quinasa
BR112017000130A2 (pt) método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
CL2015001377A1 (es) Inhbibidores de bmi-1 primidinas sustituidas inversas
NI201800042A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1
BR112016007467A2 (pt) compostos heterocíclicos e usos dos mesmos
EA201691421A1 (ru) Гетероарилы и их применение
CY1122024T1 (el) Ενωσεις αναστολης σηματοδοτησης μονοπατιου notch
EA201891626A1 (ru) Ингибиторы тирозинкиназы брутона
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
BR112017022281A2 (pt) métodos para tratar câncer
BR112019020421A8 (pt) Derivados de 2-oxo- tiazóis como inibidores de a2a e compostos para uso no tratamento de cânceres
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
CY1123576T1 (el) Συμπυκνωμενα παραγωγα θειοφαινιου χρησιμα ως αναστολεις του napi-iib

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]